FUJIFILM Biosciences and NextCell Pharma have announced the launch of a commercial research platform. 

NextCell-Cord RUO combines FUJIFILM Biosciences’ PRIME-XV MSC Expansion XSFM medium and NextCell’s MSC product derived from umbilical cord tissue. The companies say the platform will provide researchers with a more consistent, efficient, and accessible source of cells. 

NextCell-Cord RUO is available across all major global markets through FUJIFILM Biosciences, with the companies saying the platform delivers a high-quality, standardised solution for researchers working in immunology, regenerative medicine, and cell therapy development. 

“FUJIFILM Biosciences is committed to paving a better way forward with life science products, services, and solutions that serve the evolving needs of our academia, biotech, and pharmaceutical partners worldwide,” said Brandon Pence, President and Chief Operations Officer at FUJIFILM Biosciences.  

“Our strategic alliance with NextCell Pharma further strengthens our commitment to enabling our customers to achieve more with products and solutions they need every day to help create a healthier world for all.” 

“We’ve worked with FUJIFILM Biosciences to ensure that this product meets the needs of researchers and drug developers who value consistency, scalability, and translational relevance,” added Dr Lindsay Davies, Chief Scientific Officer at NextCell Pharma.  

“NextCell-Cord RUO reflects not only our clinical manufacturing expertise, but also a commitment to delivering high-quality, standardised MSC products that are scientifically robust and immediately usable in research and development workflows.”